At 4.9% CAGR, the South & Central America Pulmonary Arterial Hypertension Market is projected to be worth US$ 976.75 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the South & Central America pulmonary arterial hypertension market was valued at US$ 732.27 million in 2022 and is expected to reach US$ 976.75 million by 2028, registering a CAGR of 4.9% from 2022 to 2028. Growing incidence of pulmonary arterial hypertension and availability of generics at affordable costs due to growing patent expiration are the critical factors attributed to the South & Central America pulmonary arterial hypertension market expansion.

In pulmonary arterial hypertension (PAH), tiny arteries in lung become thick and narrow. PAH blocks the blood flow through lungs. As a result, blood pressure in the lungs increases, and heart faces difficulties to pump blood through narrowed arteries. Over the time, an individual's heart loses the ability to pump blood throughout the body effectively. PAH usually affects women in the age range from 30 to 60 years. Thus, the growing incidence of pulmonary arterial hypertension is driving the growth of the South & Central America pulmonary arterial hypertension market.

On the contrary, side effects of drugs used for treatment of pulmonary arterial hypertension hurdles the growth of South & Central America pulmonary arterial hypertension market.

Based on drugs, the South & Central America pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (eras), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. The prostacyclin and prostacyclin analogs segment held 34.6% share of South & Central America pulmonary arterial hypertension market in 2022, amassing US$ 253.30 million. It is projected to garner US$ 355.40 million by 2028 to expand at 5.8% CAGR during 2022–2028.

Based on type, the South & Central America pulmonary arterial hypertension market is bifurcated into branded and generics. The branded segment held 66.6% share of South & Central America pulmonary arterial hypertension market in 2022, amassing US$ 487.33 million. It is projected to garner US$ 659.09 million by 2028 to expand at 5.2% CAGR during 2022–2028.

Based on route of administration, the South & Central America pulmonary arterial hypertension market is segmented into oral, intravenous/ subcutaneous, and inhalational. The oral segment held 44.7% share of South & Central America pulmonary arterial hypertension market in 2022, amassing US$ 327.50 million. It is projected to garner US$ 451.96 million by 2028 to expand at 5.5% CAGR during 2022–2028.

Based on distribution channel, the South & Central America pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. The hospital pharmacies and clinics segment held 47.9% share of South & Central America pulmonary arterial hypertension market in 2022, amassing US$ 350.44 million. It is projected to garner US$ 484.19 million by 2028 to expand at 5.5% CAGR during 2022–2028.

Based on country, the South & Central America pulmonary arterial hypertension market has been categorized into Brazil, Argentina, and the Rest of South & Central America.  Our regional analysis states that Brazil captured 61.7% share of South & Central America pulmonary arterial hypertension market in 2022. It was assessed at US$ 451.93 million in 2022 and is likely to hit US$ 605.88 million by 2028, exhibiting a CAGR of 5.0% during the forecast period.

Key players profiles in  the South & Central America pulmonary arterial hypertension market report are Bayer AG; Gilead Sciences Inc; GSK Plc; Johnson & Johnson; Lupin Ltd; Novartis AG; Pfizer Inc; and Teva Pharmaceutical Industries Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com